Q-omics provides the consensus-scored NSRP1 profile across patient tissues and cancer cell-line models. NSRP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NSRP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NSRP1 protein abundance shows 26,821 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where NSRP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSRP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSRP1 survival associations across molecular data types. NSRP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSRP1 RNA expression–survival associations across cancer types. High NSRP1 expression shows unfavorable associations in UVM, ACC, HNSC, KIRP and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for NSRP1 RNA expression.
This table summarizes NSRP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NSRP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSRP1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and STAD. The HNSC box plot shows higher NSRP1 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with NSRP1 in patient tissues and cancer cell lines. In patient samples, NSRP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NSRP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
